Commodore Capital Boosts Stake in Amylyx Pharmaceuticals

Hedge fund acquires over 4 million shares of biotech firm focused on rare neurological diseases

Mar. 15, 2026 at 9:43am

Got story updates? Submit your updates here. ›

Commodore Capital LP, a hedge fund, acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the third quarter, purchasing 4,075,478 shares worth approximately $55.4 million. This represents about 3.71% ownership of the biotech company, which is developing treatments for rare and debilitating neurological conditions.

Why it matters

Amylyx Pharmaceuticals is a promising biotech firm working on innovative therapies for neurological diseases that currently have limited treatment options. Commodore Capital's significant investment signals confidence in the company's pipeline and future growth potential.

The details

According to a recent SEC filing, Commodore Capital acquired the 4,075,478 shares of Amylyx Pharmaceuticals, making it the 16th largest position in the hedge fund's portfolio. This purchase gives Commodore Capital a 3.71% stake in the biotech company. Amylyx is focused on developing small-molecule therapies designed to protect neurons and support cellular health in patients with rare neurological conditions.

  • Commodore Capital acquired the Amylyx shares in the third quarter of 2026.

The players

Commodore Capital LP

A hedge fund that has acquired a significant stake in Amylyx Pharmaceuticals, a biotech company working on treatments for rare neurological diseases.

Amylyx Pharmaceuticals, Inc.

A biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases, headquartered in Cambridge, Massachusetts.

Got photos? Submit your photos here. ›

The takeaway

Commodore Capital's investment in Amylyx Pharmaceuticals underscores the potential of the biotech firm's pipeline and the growing investor interest in innovative treatments for rare neurological conditions that currently have limited therapeutic options.